Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas A Abrams

Showing results (41-50 of 49) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 49 results.
Journal of the National Comprehensive Cancer Network : JNCCN|May 2, 2009
NCCN clinical practice guidelines in oncology: hepatobiliary cancersAl B Benson, Thomas A Abrams, Edgar Ben-Josef, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 9, 2019
Guidelines Insights: Hepatobiliary Cancers, Version 2.2019Al B Benson, Michael I D'Angelica, Daniel E Abbott, et al.
Journal for Immunotherapy of Cancer|January 25, 2024
Biomarkers of pembrolizumab efficacy in advanced anal squamous cell carcinoma: analysis of a phase II clinical trial and a cohort of long-term respondersBrandon M Huffman, Harshabad Singh, Lestat R Ali, et al.
Cancer Discovery|April 30, 2021
<i>FGFR2</i> Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in CholangiocarcinomaJames M Cleary, Srivatsan Raghavan, Qibiao Wu, et al.
Cancer Immunology Research|July 11, 2024
Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the TumorPaul E Oberstein, Andressa Dias Costa, Emily A Kawaler, et al.
JCO Precision Oncology|September 2, 2025
Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreatic CancerRishi Surana, Micaela Morgado, Ashwin Somasundaram, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 12, 2024
RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal CancerHarshabad Singh, Pranshu Sahgal, Kevin Kapner, et al.
JCO Precision Oncology|January 12, 2023
Programmatic Precision Oncology Decision Support for Patients With Gastrointestinal CancerRachel B Keller, Tali Mazor, Lynette Sholl, et al.
Nature Medicine|January 26, 2023
Combined PD-1, BRAF and MEK inhibition in BRAF<sup>V600E</sup> colorectal cancer: a phase 2 trialJun Tian, Jonathan H Chen, Sherry X Chao, et al.
Pageof 5

Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Journal of the National Comprehensive Cancer Network : JNCCN|May 2, 2009
NCCN clinical practice guidelines in oncology: hepatobiliary cancersAl B Benson, Thomas A Abrams, Edgar Ben-Josef, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 9, 2019
Guidelines Insights: Hepatobiliary Cancers, Version 2.2019Al B Benson, Michael I D'Angelica, Daniel E Abbott, et al.
Journal for Immunotherapy of Cancer|January 25, 2024
Biomarkers of pembrolizumab efficacy in advanced anal squamous cell carcinoma: analysis of a phase II clinical trial and a cohort of long-term respondersBrandon M Huffman, Harshabad Singh, Lestat R Ali, et al.
Cancer Discovery|April 30, 2021
<i>FGFR2</i> Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in CholangiocarcinomaJames M Cleary, Srivatsan Raghavan, Qibiao Wu, et al.
Cancer Immunology Research|July 11, 2024
Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the TumorPaul E Oberstein, Andressa Dias Costa, Emily A Kawaler, et al.
JCO Precision Oncology|September 2, 2025
Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreatic CancerRishi Surana, Micaela Morgado, Ashwin Somasundaram, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 12, 2024
RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal CancerHarshabad Singh, Pranshu Sahgal, Kevin Kapner, et al.
JCO Precision Oncology|January 12, 2023
Programmatic Precision Oncology Decision Support for Patients With Gastrointestinal CancerRachel B Keller, Tali Mazor, Lynette Sholl, et al.
Nature Medicine|January 26, 2023
Combined PD-1, BRAF and MEK inhibition in BRAF<sup>V600E</sup> colorectal cancer: a phase 2 trialJun Tian, Jonathan H Chen, Sherry X Chao, et al.
Pageof 5